Resmed (RSMDF) Equity Income (2018 - 2026)

Resmed has reported Equity Income for 9 years, with the latest figure at $1.7 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Income rose 130.42% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at -$2.9 million (up 82.84% YoY), and the FY2025 full-year result was $3.6 million, up 297.19% from the prior year.
• Equity Income for Q1 2026 stood at $1.7 million, up from $306000.0 in the prior quarter.
• The five-year high for Equity Income was $13.9 million in Q1 2024, with the low at -$18.8 million in Q2 2023.
• Historically, Equity Income has averaged -$2.2 million across 5 years, with a median of -$2.0 million in 2022.
• Annual changes were most pronounced in 2023 — Equity Income soared 344.31% — and 2025, when it plunged 742.78%.
• Resmed's Equity Income stood at -$2.8 million in 2022, then jumped by 33.19% to -$1.9 million in 2023, then jumped by 157.04% to $1.1 million in 2024, then plunged by 71.59% to $306000.0 in 2025, then jumped by 461.44% to $1.7 million in 2026.
• The last three Equity Income figures came in at $1.7 million (Q1 2026), $306000.0 (Q4 2025), and -$6.2 million (Q3 2025), per Business Quant data.